Randy Noelle, Ph.D.
Chairman of Scientific Advisory Board
Professor Noelle is a co-founder of Io Therapeutics. He is an internationally renowned leader in autoimmune diseases research. He holds joint academic appointments as Professor of Immunology and Microbiology at Dartmouth and Professor of Transplant Science and Immunotherapy at King’s College, London. In addition to his numerous accomplishments in academia, Professor Noelle has also demonstrated entrepreneurial translation of his research into clinical applications. He is a co-founder and Chief Scientific Officer of ImmuRx, Inc., which is developing treatments for cancer and chronic infectious diseases utilizing his discoveries in the CD40 ligand area. Professor Noelle was recently awarded a $7 M Wellcome Trust Principal Research Fellowship Award (the most prestigious of the Wellcome Trust’s personal awards) to study the role of retinoids in autoimmune disease.
Kevin Horgan, M.D.
SAB Member and Alzheimer’s Drug Development Consultant
Kevin Horgan, M.D. is a board-certified internist and gastroenterologist with extensive experience in therapeutics and diagnostics development. Dr. Horgan received his medical degree from University College, Cork, Ireland and completed training in internal medicine at the Queen Elizabeth Hospital, Birmingham, United Kingdom and at Johns Hopkins University Hospital, Baltimore, MD. Following an immunology research fellowship at the National Cancer Institute in Bethesda, MD, and a gastroenterology fellowship at the University of California at Los Angeles, he served on the UCLA faculty for four years. Dr. Horgan joined Merck in 1997 and led the development of the first neurokinin-1 receptor antagonist, EMEND®, to be approved for the prevention of chemotherapy-induced nausea and vomiting in 2003. From 2006 to 2008, he was Vice President of Clinical Immunology at Centocor Ortho Biotech Inc. In 2008, Dr. Horgan joined General Electric Healthcare as Head of Internal Medicine Research and Development in molecular diagnostics with a focus on oncology and neuroscience, where he designed the development program for GE’s amyloid PET imaging agent flutemetamol.
Allison Hulme, Ph.D.
SAB Member and Multiple Sclerosis & Alzheimer's Drug Development Consultant
Allison Hulme, Ph.D. has over 20 years pharmaceutical drug development experience spanning both large pharmaceutical and mid-sized biotechnology companies.
Dr. Hulme served as Executive Vice President and Head of Global Development at Elan Pharmaceuticals, where she also was an executive member of the Operating Committee. As Executive Vice President of Elan’s Autoimmune/Tysabri franchise, she led the clinical development, commercialization, and safety evaluation of Tysabri, obtaining regulatory approval for Tysabri in Multiple Sclerosis in the U.S. and Europe; and for Tysabri in Crohns Disease in the U.S. Dr. Hulme, also served as an executive member of the Joint Steering Committee with Biogen Idec and served as Chairman of the Joint Steering Committees between Elan and Wyeth for the development of the Alzheimer’s Immunotherapy Program and between Elan and Transition Therapeutics for the development of an early stage treatment for Alzheimer’s. She was extensively involved in business development activities at Elan, including the negotiation of the $1.5 billion deal between Elan and Johnson & Johnson for the development of bapineuzumab for Alzheimer’s disease.
Prior to joining Elan Pharmaceuticals, Dr. Hulme held positions of increasing responsibility in Clinical Research predominantly working on sumatriptan (Imitrex) for the treatment of migraine, at Glaxo Wellcome Pharmaceuticals in the United Kingdom. Prior to that Dr. Hulme served as a lecturer at Luton University. She holds a first class honors degree in science and earned her Ph.D. in Whole Cell Biosensors from Cranfield Institute of Technology in the U.K.
The company uses the law firm of K&L Gates LLP as its general and intellectual property counsel.